Cogent Biosciences News

Neutral Hold Rating on Cogent Biosciences With a $8 Price Target Amidst Clinical and Market Evaluation

TipRanksMay 14 16:48

We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth

Yahoo FinanceMay 13 20:13

HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $19 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $19 price target.

BenzingaMay 13 18:34

Buy Rating on Cogent Biosciences: Financial Stability and Promising Clinical Trials Fuel Positive Outlook

TipRanksMay 13 18:26

Analyst Issues Buy Rating on Cogent Biosciences Amid Clinical and Financial Milestones

TipRanksMay 10 13:19

Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)

TipRanksMay 8 18:10

Cogent Biosciences Price Target Maintained With a $18.00/Share by Needham

Cogent Biosciences Price Target Maintained With a $18.00/Share by Needham

Dow JonesMay 8 18:06

Needham: Reiterates the Cogent Biosciences (COGT.US) rating, adjusted from buy to buy, with a target price of $18.00.

Needham: Reiterates the Cogent Biosciences (COGT.US) rating, adjusted from buy to buy, with a target price of $18.00.

Zhitong FinanceMay 8 18:02

Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target

Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.

BenzingaMay 8 17:56

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)

TipRanksMay 8 17:40

Buy Recommendation for Cogent Biosciences Based on Promising Clinical Trials and Market Position

TipRanksMay 8 06:15

Cogent Biosciences (COGT.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.62 dollars, previous value was -0.54 dollars, and expected value was -0.51 dollars.

Cogent Biosciences (COGT.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.62 dollars, previous value was -0.54 dollars, and expected value was -0.51 dollars.

Zhitong FinanceMay 7 21:20

Cogent Biosciences | 10-Q: Quarterly report

Futu NewsMay 7 20:29 · Announcements

Cogent Biosciences Q1 EPS $(0.62) Misses $(0.51) Estimate

Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.51) by 21.57 percent. This is a 14.81 percent decrease over losses of

BenzingaMay 7 20:03

Press Release: Cogent Biosciences Reports First Quarter 2024 Financial Results

Cogent Biosciences Reports First Quarter 2024 Financial Results SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies

Dow JonesMay 7 20:00

Cogent Biosciences 1Q Loss/Shr 62c >COGT

Cogent Biosciences 1Q Loss/Shr 62c >COGT

Dow JonesMay 7 20:00

Cogent Biosciences: A Strong Buy on Oncology Asset Potential and Favorable Market Dynamics

TipRanksApr 30 05:05

Cogent Announces IPv4 Address Securitization Offering

WASHINGTON, April 25, 2024 /PRNewswire/ -- Cogent Communications Holdings, Inc. (NASDAQ: CCOI) (the "Company" or "Cogent") yesterday announced that a special-purpose, bankruptcy remote, indirect whol

PR NewswireApr 25 20:45

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) fell sharply in today's pre-market trading a

BenzingaApr 15 20:19

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

Globe NewswireApr 9 21:00